Background There were limited epidemiological data of pediatric COVID-19 in Asia outside
China, especially during the era of the variants of concern such as the Delta and Alpha …

Abstract Background: Favipiravir (FPV), an effective antiviral agent, is a drug used to treat
influenza and COVID-19 by inhibiting the RNA-dependent RNA polymerase (RdRp) of RNA …

Background Dosing recommendations for anti-infective medicines in children with pre-
existing kidney dysfunction are derived from adult pharmacokinetics studies and adjusted to …

Objective To describe the clinical characteristics and outcomes of pediatric COVID-19 in
Thailand, where favipiravir is the mainstay of antiviral treatment. Methods We conducted a …

Introduction: While the clinical course of SARS-CoV-2 infection seems to be milder or
asymptomatic within the pediatric population, growing attention has been laid to the rare …

Background Favipiravir is one of the essential antiviral drugs used for the treatment of
coronavirus disease (COVID‐19) in some countries. However, there is not enough …

Purpose To design a randomized clinical trial to assess the efficacy and safety of favipiravir
in patients with COVID-19 disease with pneumonia. Methods A randomized, double blind …

Objective The safety profile of favipiravir in patients with severe renal impairment has not
been investigated and available data are insufficient. The study aimed to compare the …

Objectives Due to limited data, this study aimed to evaluate the safety and efficacy of
favipiravir in the hospitalized pediatric population diagnosed with COVID-19. Methods The …

This study compared the pharmacokinetics and safety of favipiravir oral solution with those
of tablet formulations, which were agents repurposed to treat nonsevere coronavirus …